BC Week In Review | Jan 20, 2017
Company News

PharmAthene, Altimmune deal

PharmAthene and Altimmune will merge into a publicly traded immunotherapeutics company based in Gaithersburg. The newco will retain Altimmune’s name and trade on NYSE MKT under the ticker ALT. Altimmune shareholders will own 58.2% of...
BC Week In Review | Jan 25, 2016
Company News

PharmAthene, Siga infectious news

The Delaware Supreme Court affirmed a January 2015 Court of Chancery ruling ordering Siga to pay PharmAthene about $195 million in a case involving Siga’s Tecovirimat ( ST-246 ). Siga filed a plan of reorganization with...
BC Week In Review | Sep 7, 2015
Company News

Immunovaccine, PharmAthene deal

Immunovaccine granted PharmAthene exclusive, worldwide rights to use the DepoVax vaccine platform in the development and commercialization of a recombinant protective antigen anthrax vaccine . Immunovaccine will receive $200,000 annually and will be eligible for up...
BC Innovations | Feb 19, 2015
Translation in Brief

Single shot for anthrax

It has been over a decade since anthrax filled the headlines and while stockpiles of vaccine have been stored for emergency use, the only marketed vaccine in the U.S. - Emergent BioSolution Inc.'s BioThrax - requires three...
BC Week In Review | Feb 2, 2015
Company News

PharmAthene, Siga infectious news

The Delaware Court of Chancery court ordered Siga to pay PharmAthene $194.6 million in a case involving Siga’s smallpox antiviral Tecovirimat ( ST-246 ). The award consists of $113.1 million in lump sum expectation damages for...
BC Week In Review | Oct 6, 2014
Company News

PharmAthene, Nanotherapeutics, U.S. Department of Defense deal

PharmAthene partnered with Nanotherapeutics to advance undisclosed biodefense products from both companies' portfolios. The partners said PharmAthene's pipeline of products to prevent and treat emerging infectious diseases and biodefense threats fits well with Nanotherapeutics' manufacturing...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BC Week In Review | Sep 29, 2014
Company News

PharmAthene, NIH infectious news

PharmAthene received a contract worth up to $28.1 million from NIH's National Institute of Allergy and Infectious Disease (NIAID) to develop its preclinical thermostable anthrax vaccine based on the company's recombinant protective agent vaccine technology....
BC Week In Review | Sep 22, 2014
Company News

Siga, U.S. Department of Health and Human Services infectious news

Siga filed for Chapter 11 bankruptcy U.S. Bankruptcy Court for the Southern District of New York and said the court granted "first-day" motions, which Siga said will assure that the company's operations will continue throughout...
BC Week In Review | Sep 1, 2014
Company News

PharmAthene, Siga, U.S. Department of Health and Human Services infectious news

PharmAthene disclosed in its 2Q14 earnings that it reduced R&D headcount by 11, or 33% of its technical staff. The cuts were in response to an April notice from HHS’s Biomedical Advanced Research and Development...
Items per page:
1 - 10 of 157
BC Week In Review | Jan 20, 2017
Company News

PharmAthene, Altimmune deal

PharmAthene and Altimmune will merge into a publicly traded immunotherapeutics company based in Gaithersburg. The newco will retain Altimmune’s name and trade on NYSE MKT under the ticker ALT. Altimmune shareholders will own 58.2% of...
BC Week In Review | Jan 25, 2016
Company News

PharmAthene, Siga infectious news

The Delaware Supreme Court affirmed a January 2015 Court of Chancery ruling ordering Siga to pay PharmAthene about $195 million in a case involving Siga’s Tecovirimat ( ST-246 ). Siga filed a plan of reorganization with...
BC Week In Review | Sep 7, 2015
Company News

Immunovaccine, PharmAthene deal

Immunovaccine granted PharmAthene exclusive, worldwide rights to use the DepoVax vaccine platform in the development and commercialization of a recombinant protective antigen anthrax vaccine . Immunovaccine will receive $200,000 annually and will be eligible for up...
BC Innovations | Feb 19, 2015
Translation in Brief

Single shot for anthrax

It has been over a decade since anthrax filled the headlines and while stockpiles of vaccine have been stored for emergency use, the only marketed vaccine in the U.S. - Emergent BioSolution Inc.'s BioThrax - requires three...
BC Week In Review | Feb 2, 2015
Company News

PharmAthene, Siga infectious news

The Delaware Court of Chancery court ordered Siga to pay PharmAthene $194.6 million in a case involving Siga’s smallpox antiviral Tecovirimat ( ST-246 ). The award consists of $113.1 million in lump sum expectation damages for...
BC Week In Review | Oct 6, 2014
Company News

PharmAthene, Nanotherapeutics, U.S. Department of Defense deal

PharmAthene partnered with Nanotherapeutics to advance undisclosed biodefense products from both companies' portfolios. The partners said PharmAthene's pipeline of products to prevent and treat emerging infectious diseases and biodefense threats fits well with Nanotherapeutics' manufacturing...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BC Week In Review | Sep 29, 2014
Company News

PharmAthene, NIH infectious news

PharmAthene received a contract worth up to $28.1 million from NIH's National Institute of Allergy and Infectious Disease (NIAID) to develop its preclinical thermostable anthrax vaccine based on the company's recombinant protective agent vaccine technology....
BC Week In Review | Sep 22, 2014
Company News

Siga, U.S. Department of Health and Human Services infectious news

Siga filed for Chapter 11 bankruptcy U.S. Bankruptcy Court for the Southern District of New York and said the court granted "first-day" motions, which Siga said will assure that the company's operations will continue throughout...
BC Week In Review | Sep 1, 2014
Company News

PharmAthene, Siga, U.S. Department of Health and Human Services infectious news

PharmAthene disclosed in its 2Q14 earnings that it reduced R&D headcount by 11, or 33% of its technical staff. The cuts were in response to an April notice from HHS’s Biomedical Advanced Research and Development...
Items per page:
1 - 10 of 157